Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | LTK | P29376 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760779 | 0.73 | NOS1 (0.36) | NOS1FGFR1MAPTTRPA1HSP90AA1 | |
| SCHEMBL19153196 | 0.73 | MAPT (0.47) | NOS1FGFR1MAPTTRPA1HSP90AA1 | |
| SCHEMBL19249524 | 0.73 | NOS1 (0.36) | NOS1FGFR1MAPTTRPA1HSP90AA1 | |
| SCHEMBL19332837 | 0.73 | NOS1 (0.55) | NOS1FGFR1DYRK1AMAPTHSP90AA1 | |
| SCHEMBL14206720 | 0.72 | NOS1 (0.45) | NOS1FGFR1DYRK1AMAPTHSP90AA1 | |
| SCHEMBL204492 | 0.71 | NOS1 (0.53) | NOS1FGFR1DYRK1AMAPTTRPA1 | |
| SCHEMBL104360 | 0.71 | NOS1 (1.00) | NOS1FGFR1DYRK1AMAPTTRPA1 | |
| SCHEMBL14911997 | 0.71 | ALDH1A1 (0.40) | NOS1FGFR1DYRK1AKDM4EHPGD | |
| SCHEMBL4302971 | 0.70 | NOS1 (0.52) | NOS1FGFR1DYRK1AMAPTTRPA1 | |
| SCHEMBL20129740 | 0.68 | TRPA1 (0.37) | NOS1MAPTTRPA1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4504716-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| CN-119156381-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-4450502-A1 | AZAINDOLE DERIVATIVE INHIBITING H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401522-A | Azaindole derivatives inhibiting H-PGDS | 佐藤制药株式会社 | 2024-07-26 | — | — | CN | disclosed |
| WO-2023193760-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023113023-A1 | AZAINDOLE DERIVATIVE INHIBITING H-PGDS | 佐藤製薬株式会社 | 2023-06-22 | — | — | WO | disclosed |
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | HPGDS, PTGIS, HPGD | NOS1 198/4885FGFR1 4103/4885DYRK1A 3281/4885 |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | NOS1 1108/4885FGFR1 280/4885DYRK1A 2883/4885 |
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | NOS1 2621/4885FGFR1 812/4885DYRK1A 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.